Novo Nordisk Pharmaceutical Industries LP
Novo Nordisk's Clayton facility manufactures insulin, GLP-1 products and prefilled delivery devices for the treatment of diabetes. An API facility is presently under construction in Clayton adjacent to the existing manufacturing site.
Employment range in NC
Primary site activity
All company activities
Products on market
Insulin and GLP-1 products and delivery devices, growth hormone, hemostasis management, hormone replacement therapy